Genscript Biotech to spin off unit in $100m Nasdaq IPO

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Asia

Genscript Biotech to spin off unit in $100m Nasdaq IPO

Jonathan Breen
May 14, 2020 06:30 am
pills adobe stock 575x375 pharmaceuticals
Heap of medical pills in white, blue and other colors. Pills in plastic package. Panoramic banner for design. | OKSANA KAZYKINA/okskaz - stock.adobe.com

Genscript Biotech Corp is planning to spin-off and list subsidiary Legend Biotech Corp in a potential $100m Nasdaq IPO. The firm submitted listing documents to the US regulator on Wednesday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • ✔ 4,000 annual insights
  • ✔ 700+ notes and long-form analyses
  • ✔ 4 capital markets databases
  • ✔ Daily newsletters across markets and asset classes
  • ✔ 2 weekly podcasts

Topics

JP MorganEquity IPOsHealth and BiotechEquityAmericasJefferies LLCHong Kong SARAsiaGreater ChinaMorgan StanleyNortheast AsiaAsia PacificUnited StatesEmerging MarketsNorth AmericaSRI
JB
Jonathan Breen
Equities editor GlobalCapital Asia
Contact
Gift this article